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1. Introduction
Ischemia-Reperfusion (I/R) injury is an important cause of liver damage occurring during
surgical procedures including hepatic resections and liver transplantation (LT) [1-3]. The
shortage of organs has led centers to expand their criteria for the acceptance of marginal
grafts that exhibit poor tolerance to I/R [4]. Some of these include the use of organs from old‐
er donors and grafts such as small-for-size or steatotic livers. However, I/R injury is the un‐
derlying cause of graft dysfunction in marginal organs [4]. Indeed, the use of steatotic livers
for transplantation is associated with an increased risk of primary nonfunction or dysfunc‐
tion after surgery [5]. In addition, the occurrence of postoperative liver failure after hepatic
resection in a steatotic liver exposed to normothermic ischemia has been reported [6]. A
large number of factors and mediators play a part in liver I/R injury. The relationships be‐
tween the signalling pathways involved are highly complex and it is not yet possible to de‐
scribe, with absolute certainty, the events that occur between the beginning of reperfusion
and the final outcome of either poor function or a non-functional liver graft. We will show
that the mechanisms responsible for hepatic I/R injury depends on the experimental model
used, who are valuable tool for understanding the physiopathology of hepatic I/R injury and
discovering novel therapeutic targets and drugs. Several strategies to protect the liver from
I/R injury have been developed in animal models and, some of these, might find their way
into clinical practice. The species used for experimental investigation of hepatic I/R injury
range from mice to pigs. The book chapter will discuss the numerous experimental models
used to study the complexity of hepatic I/R injury, data reported in choice of the animal
model, when selecting an animal species, the age, the sex, the degree of steatosis…etc. Thus,
the different strengths and limitations of the different experimental models will be dis‐
cussed. Also the standardized experimental conditions, such as anesthetic and analgesic
procedures will be described. We also attempt to highlight the fact that the types of ischemia
(cold and warm ischemia) play an important role in experimental liver surgery. The most
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existing reviews concerning about mechanisms responsible of I/R does not make a distinc‐
tion between cold and warm ischemia. We will discuss the different experimental models of
normothermic ischemia including global hepatic ischemia with portocaval decompression,
global liver ischemia with spleen transposition and partial liver ischemia. Among the differ‐
ent experimental models of cold hepatic I/R injury, we will described the different experi‐
mental models used, including a section on orthotopic liver transplantation (OLT) because it
is a common yet and complex microsurgical technique. In an attempt to expand the size of
the donor pool, the different surgical techniques including reduced-size liver transplanta‐
tion (RSLT), split liver transplantation (SLT) and living donor liver transplantation (LDLT)
will be mentioned in the book chapter. In line with this, the optimization of graft function
and survival through the static organ preservation and machine perfusion will also dis‐
cused. Static organ preservation was a breakthrough and remains the conventional method
of preservation. The machine perfusion has emerged as a suitable strategy for preserving
liver grafts with promising data over the past decade, especially when marginal organs such
as steatotic liver are used for transplantation. The strengths and disadvantages of the differ‐
ent types of machine perfusion (normothermic, hypothermic and subnormothermic machine
perfusion) will be discussed. Furthermore some factors, including the duration and extent of
hepatic ischemia, starvation, graft, age, and steatosis-which must be considered before the
selection of an experimental model of hepatic I/R-will be mentioned. All of these factors con‐
tribute to enhancing liver susceptibility to I/R injury. In line with this, we will focused on the
negative effects of ischemia on liver regeneration in both normal and marginal livers when
they are subjected to liver surgery associated with hepatic resections or LT. The different ex‐
perimental models of hepatic I/R in which both conditions-ischemia and resection- are
present will be described.
2. Hepatic ischemia-reperfusion injury
Due to the complexity of hepatic I/R injury, the present review summarizes the established
basic concepts of the mechanisms and cell types involved in this process (Fig. 1). The imbal‐
ance between nitric oxide (NO) and endothelin production, contributes to microcirculatory
diseases associated with I/R. Concomitantly, the activation of Kupffer cells (KC) releases re‐
active oxygen species (ROS) and proinflammatory cytokines, including tumour necrosis fac‐
tor-α (TNF-α) and interleukin-1 (IL-1) [7-9]. ROS can also derive from mitochondria and the
xanthine dehydrogenase/xanthine oxidase (XDH/XOD) pathway in activated SEC and hepa‐
tocytes. Cytokines promote neutrophil activation and accumulation, thereby contributing to
the progression of parenchymal injury by releasing ROS and proteases [7,10]. Capillary nar‐
rowing also contributes to hepatic neutrophil accumulation [11]. Besides, IL-1 and TNF-α re‐
cruit and activate CD4+ T-lymphocytes, which produce granulocyte-macrophage colony-
stimulating factor (GM-CSF), interferon gamma (INF-γ) and TNF-β. These cytokines
amplify KC activation and TNF-α and IL-1 secretion and promote neutrophil recruitment
and adherente into the liver sinusoids [12]. Platelet activating factor can prime neutrophils
for ROS generation, whereas leukotriene B4 (LTB4) contributes to the amplification of the
neutrophil response [7,10]. In addition, I/R initiates protein misfolding in the endoplasmic
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reticulum (ER), which can activate a highly conserved unfolded protein response (UPR) sig‐
nal transduction pathway. The UPR is characterized by coordinated activation of three ER
transmembrane proteins, inositol-requiring enzyme 1 (IRE1), PKR-like ER kinase (PERK)
and activating transcription factor (ATF)-6. If the damage is so severe that homeostasis can‐
not be restored, ER stress signal transduction pathways ultimately initiate apoptosis and ne‐
crosis [9]. In addition to the high ROS level–generating system found in liver grafts shows
low levels of antioxidants such as glutathione (GSH) and superoxide dismutase (SOD) [1,9].
Alterations in the renin-angiotensin system (RAS), retinol binding protein 4 (RBP4), adipo‐
nectin and peroxisome proliferator activated receptor gamma (PPARγ) contribute to oxida‐
tive stress. Toll like receptor (TLR4) signaling pathway is also responsible for the hepatic I/R
damage. Myeloid differentiation primary response gene 88 (MyD88) and TIR-domain-con‐
taining adapter-inducing interferon-β (TRIF) activate intracellular signaling cascades that ul‐
timately trigger an inflammatory response [9,13].
Figure 1. Mechanisms involved in hepatic ischemia-reperfusion injury. ATP, adenosine triphosphate; Cyt c: cytochrome
c; EC, endothelial cell; ET, endothelin; GM-CSF, granulocyte-macrophage colony-stimulating factor; GSH, glutathione;
ICAM, intracellular cell adhesion molecule; IFN α/β, interferon α/β; IL, interleukin; INF, interferon; IRE1, inositol-requir‐
ing enzyme 1; KC, kupffer cell; LTB4, leucotriene B4; MyD88, myeloid differentiation primary response gene 88; NO,
nitric oxide; ONOO-, peroxynitrite; PAF, platelet activating factor; PERK, protein kinase-like endoplasmic reticulum kin‐
ase; PPARγ, peroxisome proliferator-activated receptor γ; RBP4, retinol binding protein 4; Renin-Angiotensin system
(RAS): Ang II and Ang 1-7, angiotensin; ROS, reactive oxygen species; SLP, secretory leukocyte protease inhibitor; SOD,
superoxide dismutase; TLR4, toll-like receptor 4; TNF, tumor necrosis factor; TRAF6, TNF receptor-associated factor 6;
TRIF, TIR-domain-containing adapter-inducing interferon- β; UPR/ER, unfolded protein response/endoplasmic reticu‐
lum; VCAM, vascular cell adhesion molecule; X/XOD, xanthine/xanthine oxidase




Experimental surgery is an activity within the scientific development, offering a wide range
of possibilities for the progress of medicine. As a discipline can be accessed from various
branches of science and allows testing and development of surgical procedures and learning
the scientific method, so that, working with laboratory animals has been and is required
prelude to innovation and development of advances in clinical surgery. The reproduction
and validation of experimental models has facilitated the extrapolation of the knowledge ac‐
quired to Medicine [16]. The animals used in research models have been divided into four
groups: spontaneous, induced, negative and orphans. 1) The spontaneous or non-manipu‐
lated models are obtained by selection of inbred animals that express a variable or among
populations in which a large number of animals that express variable; 2) Induced or manip‐
ulated models are obtained by an experimental challenge that can be classified into five
groups: A. Administration of biologically active substances, eg., induction of steatosis after
alcohol ingestion. B. Surgical manipulation, such as partial hepatectomy (PH) for the study
of liver regeneration. C. Administration of modified diets, lack or surplus components, e.g.,
in the study of hyperlipidemia. D. Genetic manipulation and transgenic animals which pro‐
duce special models that are being helpful in understanding mechanisms of pathogenesis
and therapy. 3) The negative patterns are those in which a given variable does not develop.
The interest is in studying the mechanisms that provide resistance. 4) Orphan models are
those expressing an unknown variable in humans [16].
The speed of human studies is slow, the majority of human tissues are not routinely accessi‐
ble for research purposes, and there is a very limited opportunity for interventional studies.
Although scientific research has always relied on the use of cell cultures, information that is
obtained through in vitro studies can be extrapolated to biomedical research only when ana‐
lyzed within a complex organism with metabolic functioning. Therefore, one avenue hold‐
ing tremendous potential in the search for therapies against I/R damage is the use of intact
living systems, in which complex biological processes can be examined. There are many ad‐
vantages of animal studies: large numbers of animals (especially rodents) can be bred and
studied, interventional studies can be performed, and established and emerging tools for
targeted manipulation of gene expression levels provide insight into the function of media‐
tors in hepatic I/R injury.
Comparison of the results of animal studies and their extrapolation to human beings is feasi‐
ble, but with limitations. Among the primary obstacles are differences in hypothermia and
ischemia tolerance, differences in the anatomy of the livers of various species and subspe‐
cies, differences between and within the experimental models used, and differences in the
modes of administration, dosage, and metabolic breakdown of the drugs under investiga‐
tion. Thus, it is very important to choose the animal species and the experimental model and
to standardize the protocol according to the clinical question under study.
Small and large animals have their own advantages and disadvantages but the ultimate
choice of animal species depends essentially on the scientific problema in question. Small
animals such as mice and rats are exceptionally useful because they are easy to manage,
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present minimal logistical, financial, or ethical problems, and provide the potential for ge‐
netic alterations (e.g., transgenic and knockout animals). However, an important drawback
is that the results of studies performed in small animals are of limited applicability to hu‐
man beings due to their varying size and anatomy of the liver and their faster metabolism
[17]. Large animals such as pigs, sheep, and dogs exhibit greater similarity in their anatomy
and physiology to human beings. Thus, they are more suited for the study of problems of
direct clinical relevance. However, their use is restricted by serious logistical and financial
difficulties and often by ethical concerns. Furthermore, the technical possibilities of blood
and tissue processing are extremely restricted because of the limited availability of immuno‐
logical tools for use in large animal species [17].
Extensive data exist on liver anatomy in various species of animals, but a few examples of
species variations will suffice to prove that caution is warranted in the extrapolation of this
data to humans. Mice and rats each have 4 liver lobes: median (or middle), left, right, and
caudate and all, except the left, are further subdivided into 2 or more parts. Human liver
lobes can be subdivided into 9 segments based on the vascular and ductal branching pat‐
terns to the right and lefts sides. The hepatic lobes of the rat appear to have similar funda‐
mental portal and hepatic venous systems, and thus segments, comparable to that of human
liver. The vascular systems to or from lobes show individual variations in humans as well as
in rats. In humans and other mammals, sinusoids drain only into the terminal hepatic veins
whereas in the rat sinusoids enter the hepatic venous system at all levels of the hepatic ve‐
nous tree. In rats, unlike humans, the sinusoids are supplied not only by the terminal portal
venules but also directly from larger venous branches. In addition, rat livers lack the septal
vein branches, which are present both in humans and pigs [18]. The presence of arterio-por‐
tal anastomosis is very frecuent in rats but not in hamsters and humans. The rat is unique in
possessing a perihilar biliary plexus, which is present from the large hiliar portal tracts to
smaller portal tracts. An equivalent, less developed structure exists in humans only in large
portal tracts. The biliary system in pigs lacks this plexus altogether, but contains numerous
side pouches throughout the course of the bile duct [18,19]. Mice and humans have a gall
bladder, but not the rat. Significant difference is present among the species with respect to
the extent of hepatic parenchymal innervation and the human has the most abundant sup‐
ply of autonomic nerves in the intraparenchymal region [20]. Differences in hepatic cell
types have been reported depending of species evaluated. For example, regarding to endo‐
thelial cells, rats have relatively higher fenestrae compared to some other species. Defenes‐
tration is though to play a role in some liver diseases [18]. Intrinsic biochemical differences
between the hepatocytes of the various species have been also reported. Rats and mice are
extremely sensitive to the response of peroxisome proliferators, hamsters show a less
marked response while primates and humans are insensitive or non-responsive [21]. There
are two principle hypotheses to explain species differences in response to PPs: quantity of
PPARa and/or the quality of the PPARα-mediated response [22].
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When selecting an animal species, the age and sex of the animals should be considered. De‐
pending on the duration of ischemia, young (35–50 g) and older rats (250–400 g) exhibit sig‐
nificant differences in their hepatic microcirculation [23]. A mature rat weighing more than
250 g (14–16 weeks old) is the most suitable because younger rats can present technical
problems, whereas older rats are more prone to respiratory infections and fat accumulation.
Sex selection also affects experimental results, as hormone levels in female animals are de‐
pendent on the estrous cycle, which certainly affects the ischemia tolerance of the liver. For
instance, a study demonstrated that after normothermic liver ischemia, male rats were less
sensitive to reperfusion injury than female rats.
Considering the relevancy of hepatic steatosis in surgery, experimental models of hepatic
I/R injury in the presence of steatosis have been developed. However, the mechanisms in‐
volved in hepatic I/R injury, as it will be described in following sections, are different de‐
pending on the method used to induce steatosis. The different models of steatosis include 1)
induced genetic models; 2) animals fed diets with high levels of saturated fat and/or carbo‐
hydrates and/or proteins; 3) animals fed diets deficient in methyl groups (choline, methio‐
nine, folates); and 4) animals fed modified high-fat diets (lower methionine and choline and
higher-fat content).
The induction of I/R injury must be performed under standardized experimental conditions.
Of primary importance are the conditions under which the animals are kept such as ade‐
quate acclimatization time, maintenance under climatized conditions with 12 hours light / 12
hours darkness, and standardized diets. The anesthetic method and postoperative analgesic
regimen must also be standardized. When choosing the anesthetic and analgesic procedures,
possible interactions with liver metabolism must be considered. Attention must be paid to
adequate monitoring of blood pressure, heart rate, and body temperature.
4. Normothermic hepatic ischemia
4.1. Global hepatic ischemia with portocaval decompression
The model of global liver ischemia with portal decompression ideally simulates the clinical
situation of warm ischemia after the Pringle maneuver for liver resection and LT. The first
successful shunt operation in humans was performed by Vidal in 1903 [24]. Blakemore was
one of the first workers to report successful portal-systemic anastomosis in rats working
principally with endothelium-lined tubes [25]. Burnett et al., modified this technique to form
a portocaval shunt [26]. In 1959 Bernstein and Cheiker developed the portosystemic shunt
that conducted the portal blood after functional hepatectomy into one of the iliac veins [27].
In small animals, in addition to many other shunt techniques such as the portofemoral shunt
and the mesentericocaval shunt via the jugular vein, in 1995, Spiegel et al., developed the
splenocaval shunt [28] (Figure 2).
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Figure 2. Models of global normotermic liver ischemia. A) Pringle-maneuver. B) Splecnocaval shunt. C) Portojugular
shunt. D) Spleen transposition.
4.2. Global liver ischemia with spleen transposition
Bengmark et al., developed this model in 1970 for the surgical treatment of portal hyperten‐
sion [29]. In 1981 Meredith and Wade presented a rat model that by transposition of the
spleen produced a portosystemic shunt in the anhepatic rat [30]. A small incision is made in
the left hypochondrium. After transposition of the spleen into a subcutaneous pouch, ade‐
quate portosystemic anastomoses arise after two to three weeks (Figure 2). Reversal of blood
flow in the splenic vein, induced by the transposition, stimulates angiogenesis. In the second
step 2 weeks later, the surgeon performs a median laparotomy and temporary occlusion of
the hepatoduodenal ligament. This decompression by spleen transposition does not require
microsurgical technique and is therefore easy to perform. Two-to-three weeks postopera‐
tively, the spleen will have been encapsulated without any signs of bleeding or inflamma‐
tion. One disadvantage of this model is the long time lapse (3 weeks) until the formation of
adequate portosystemic collaterals. Not until this point in time are the collaterals sufficiently
large to take over portal vein flow completely. Furthermore, it is uncertain how the changes
in hepatic inflow will react upon the collaterals [31].
4.3. Partial liver ischemia and liver regeneration
In 1982, Yamauchi et al., described a model of hepatic ischemia [32]. In this technique, ische‐
mia is induced by occlusion of the hepatic artery, the portal vein, and the bile duct of the left
and median lobes. An extracorporeal shunt is not necessary because blood flow continues
through the right and caudal liver lobes. This model of 70% partial ischemia has been wide‐
ly used in experimental studies of hepatic I/R [13,33]. Additionally, an experimental model
of 30% partial liver ischemia has been used in which blood supply to the right lobe of the
liver is interrupted by occlusion at the level of the hepatic artery and portal vein [34]. It is
known that, in clinical situations, PH under I/R is usually performed to control bleeding
during parenchymal dissection. In vitro studies, although they have proved helpful in dis‐
closing the signal transmission pathways of various hepatocyte mitogens, need to be supple‐
mented by in vivo studies with experimental animals so as to simulate the interactions
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between the various cell populations of the liver. Different strategies have been adopted for
the experimental induction of liver regeneration as follow below [35]. On the other hand, the
use of an experimental model including both hepatic regeneration and I/R injury is advisa‐
ble to simulate the clinical situation of selective or hemihepatic vascular occlusion for liver
resections. In experimental model, after resection of left hepatic lobe, a microvascular clamp
is placed across the portal triad supplying the median lobe (30%). Congestion of the bowel is
avoided during the clamping period by preserving the portal flow through the right and
caudate lobes. At the end of ischemia time, the right lobe and caudate lobes are resected,
and reperfusion of the median lobe is achieved by releasing the clamp. This model of hepat‐
ic resection does not require any portal decompression and also fulfills certain important cri‐
teria such as reversibility, good reproducibility, and simple performance [36].
4.4. Other experimental models of liver regeneration – Regeneration after liver injury
There are large numbers of toxins that can cause liver damage and cell death in the liver pa‐
renchyma followed by liver regeneration. Carbon tetrachloride, d-galactosamine, ethanol,
thioacetamide and acetaminophen are the hepatotoxins that have been most frequently em‐
ployed to induce experimental liver regeneration in the hope of answering various ques‐
tions [35]. In contrast to PH, these so-called hepatotoxic models of liver regeneration are
easier to perform and of greater clinical relevance. Whereas PH leaves all the remaining hep‐
atic acini intact, hepatotoxins can be used selectively to induce centrilobular or periportal
necrotic lesions and can thus better simulate certain liver diseases. One serious weakness of
toxin-induced liver regeneration is the por reproducibility and standardisability of the mod‐
els, because the local and systemic effects of the toxin depend on the dose, the mode of ad‐
ministration, the species of animals, their age and nutritional status and other factors, and
the extent of the liver injury and the regeneration can vary accordingly. The regenerative re‐
sponse of the liver is often determined by the dose and mode of administration. Further‐
more, the toxins can directly interfere with the cellular and molecular mechanisms of liver
regeneration, e.g., by damaging membranes (interruption of the interaction between growth
factors and membrane receptors), impairment of gene expression and protein synthesis, in‐
flammatory reactions (increased production of cytokines and oxygen radicals) or activation
of nonparenchymal cells [37]. Finally, in these toxic models the processes of liver injury and
repair are closely interwoven, a fact that adds to the difficulties of investigating liver regen‐
eration. It is therefore difficult to predict the extent of liver damage and liver regeneration
and to avoid significant variability between individual experiments [35].
5. Liver transplantation
The development and implementation of different surgical techniques in LT have been
based upon animal experimental studies. LT in larger laboratory animals such as dogs and
pigs is technically easier. However, the rat has become the most important subject for exper‐
imental LT because of, among other factors, the availability of genetically defined animals
[38]. The first experimental liver replacement with OLT was reported by Cannon in 1956,
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but none of those dogs survived [39]. Surgical techniques for experimental OLT on pigs
were started by Garnier et al., in 1965 [40]. OLT in mice is technically very difficult, even
without reconstruction of the hepatic artery. By contrast, OLT in rats is technically accessi‐
ble, producing more clinically relevant and reliable data [41]. The development of clinically
relevant OLT models in rats [41] has advanced clinical knowledge in LT. These experimental
models facilitate the study of new preservation methods, tolerance induction, rejection
mechanisms, and novel immunosuppressor therapies [42].
The first model of OLT in the rat was described by Lee et al., in 1973 using hand-suture tech‐
niques [43]. This technique includes standard microvascular suture technique for venous
anastomoses and a miniaturized extracorporeal portal-tojugular shunt (“microsuture mod‐
el”). Rearterialization of the graft is performed by anastomosing the donor aorta end-to-side
to the host aorta, and the donor bile duct is implanted into the duodenum [43]. Two years
later, in 1975, Lee reported a modified model without hepatic artery reconstruction and tem‐
poral shunt of the portojugular venovenous bypass [44]. However, these models were not
widely used due to the prolonged surgical time and technical demand. In 1979, Zimmer‐
mann introduced a microsuture model [45] that is similar to the simplified model of Lee
[44]. He developed a new technique for bile duct reconstruction that preserves the sphincter
of ampulla “splint technique”. In the same year, Kamada and Calne [46] developed a cuff
technique for anastomoses of portal vein and bile duct to simplify Lee’s model and especial‐
ly to shorten the anhepatic time and reduce biliary complications. With the cuff method be‐
ing introduced by Kamada and Calne [46], OLT in rats without hepatic artery reconstruction
became globally accepted [41]. Other models introduced by later investigators contain for
the most part only a few modifications. In 1980 Miyata introduced the “three-cuff model’’
[47] with cuff technique for the three venous anastomoses. Bile duct anastomosis is per‐
formed by using the splint technique first described by Zimmermann [45], in which reestab‐
lishment of hepatic blood flow is not carried out. Anastomosis of the portal vein is done by
the method of Kamada and Calne [46]. For connecting the bile duct, splint technique was
used [47]. In 1982 Engemann [48] devised a microsuture model that corresponds closely to
the model of Lee [43]. During the anhepatic time he dispensed with portosystemic bypass
and used an aortic-celiac segment for rearterialization. This had been already prepared in
the donor operation, and anastomosed end-toside to the infrarenal aorta of the recipient.
Bile duct anastomosis is performed using the splint technique [48]. Portal vein clamping
causes a rise of endotoxin in the portal vein, which could lead to disturbances in hepatic mi‐
crocirculation. Lee was the first to use a portosystemic shunt, but in further models it has
not been established because the acceleration of the transplantation procedure by improved
anastomotic techniques was expected to preclude the need for this complicated operative
procedure [38]. Kitakado completed the “two-cuff model” in 1992 by developing a bioab‐
sorbable material (synthesis of D, L-lactic acid and glycolic acid). Its in vivo degradation time
is about 4 months when used for cuff anastomosis of portal vein and infrahepatic vein cava
[49]. He established a longterm model in OLT in rat. This surgical procedure is usually per‐
formed according to the procedure described by Kamada and Calne [46]. After arterial and
portal perfusion, the suprahepatic vena cava is dissected free from the diaphragmatic ring,
and the intrathoracic vena cava is transected. The aorta is cut around the celiac axis to form
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the aortic patch. Finally, the inferior vena cava, the portal vein, and the bile duct are cut, and
the graft is placed in a cold preservation solution (Figure 3). OLT is then performed by su‐
ture or mechanical microvascular anastomoses. Sutured vascular anastomosis reduces the
incidence of thrombosis but takes a long time to perform. Suprahepatic vena cava anastomo‐
sis is performed by the continuous suturing technique. Then, portal vein and infrahepatic
vena cava anastomosis is performed in the same manner. Hepatic artery reconstruction in
rat LT can prevent bile duct ischemia and preserve the structure of the liver [50]. Several
techniques of rearterialization by suture have been proposed [50], the best being the aortic
segment anastomosis technique. After rearterialization, the common bile duct is anasto‐
mosed. OLT by hand-sewn microanastomosis is a very useful method because this techni‐
que comes closest to the techniques used in human transplantation surgery. Alternatively,
livers can be satisfactorily allografted in rats by using the rapid cuff-ligature technique for
anastomosis [46]. In the simplified technique, the donor hepatic artery can be ligated be‐
cause it will not be anastomosed [42].
Figure 3. Liver transplantation procedure. A) Suprahepatic cava vein prepared for the anastomosis. B) Inferior vein
cava cuff attachment. C) Anhepatic phase in the recipient rat. D) Anastomosis of suprahepatic cava vein by continuous
suture. E) Portal vein anastomosis trhough the cuff method. F) Anastomosis of the bile duct.
6. Strategies to expand the size of the donor pool
In an attempt to expand the size of the donor pool, a number of surgical techniques have
been developed over the past 15 years, including reduced-size liver transplantation (RSLT),
split liver transplantation (SLT) and living donor liver transplantation (LDLT) [51]. For chil‐
dren and small adult recipients, RSLT has been developed to maximize the use of donor or‐
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gans. Bismuth and Houssin in 1984, transplanted the left lateral segment of the left liver lobe
from a cadaveric donor into a small child and discarded the remainder of the donor liver
[52]. Couinaud’s anatomical classification permits the creation of partial liver allografts from
either deceased or living donors. Couinaud’s classification divides the liver into eight inde‐
pendent segments, each of which has its own vascular inflow, outflow, and biliary drainage
[53]. Segments IV to VIII are used for adults, whereas left lateral lobes (Segments II and III)
or left lobes (Segments II, III, and IV) are used for pediatric recipients. Bleeding, bilomas,
and portal vein thrombosis are complications related to the procedure itself, which are asso‐
ciated with an increased number of re-operation. SLT, first performed in 1988, allows the di‐
vision of the adult donor liver, together with its vascular and biliary structures, into two or
more functional grafts, which can be transplanted into two or more recipients [54]. Liver
splitting is performed either ex situ or in situ. So far, there is no consensus on which techni‐
que is superior because both techniques demonstrate similar patient and graft survival rates
compared with whole liver grafting [54]. Biliary complications occur in 22% of recipients. In
1990, Broelsch et al., reported the first 20 series of LDLT in the USA [55]. In 1996, Lo et al.,
[56] performed the first successful LDLT using an extended right lobe from a living donor
for an adult recipient. One of the benefits of reduced-size grafts from living donors is a graft
of good quality with a short ischemic time, this latter being possible because live donor pro‐
curements can be electively timed with the recipient procedure. Conversely, the major con‐
cern over the application of LDLT for adults is graft-size disparity. Small grafts require
posterior regeneration to restore the liver/body ratio. A small graft may result in malfunc‐
tion or the small for size syndrome in which the recipient fails to sustain adequate metabolic
function. It is well known that I/R significantly reduce liver regeneration after hepatectomy.
Thus, the identification and subsequent modulation of mechanism that are involved in liver
injury and regeneration might favor the recovery and functioning of the transplanted organ.
To mimic some of the pathophysiological events that occur during such clinical situations,
several experimental models of RSLT have been developed. For example, OLT with the im‐
plantation of liver grafts that approximated 30%–70% of the normal mass of a rat liver has
been performed. Graft size is important for normal liver function and host survival [51]. It
has been reported that 100% of recipient rats that were implanted with 40%, 50%, 60%, or
70% of the liver survived regardless of the duration of preservation. This suggests that graft
sizes of 40% or greater are sufficient to meet the metabolic demands of the recipients. The
transplantation of a graft of 30% of the normal liver mass provides an extreme model of hep‐
atic reduction that presumably stimulated a maximal regenerative response [51]. Three pos‐
sibilities exist with respect to the timing of the graft reduction: in the donor before
perfusion, in the container (ex situ), or in the recipient after reperfusion. If the reduction is
done in vivo prior to the removal of the donor liver, then two concerns exist: 1) excessive
bleeding might stimulate systemic responses that could alter the liver and 2) the immediate
phase of the regeneration response could be initiated in the donor animal. The second
choice, ex situ reduction, can be done without the risk of damaging the graft by manipula‐
tion or affecting anastomosis after reperfusion. Finally, resection of the graft after implanta‐
tion in the recipient adds surgical stress and the risk of bleeding.
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7. Modes of organ preservation and optimizing the graft
The ideal method of organ preservation should: 1) Reverse injury sustained during donor
death and organ procurement; 2) Provide viability testing; 3) Prolong safe preservation time
and 4) Improve the graft quality [57]. There are currently 2 modes of preservation methods
for livers: static and dynamic (Figure 4). Simple cold storage is the main method for static
storage while hypothermic machine perfusion (HMP) and normothermic machine perfusion
(NMP) comprise some of the methods for dynamic preservation. Of these methods, only
simple cold store is roved clinically for livers. The remaining methods are in various stages
of pre-clinical and early clinical studies. Dynamic preservation methods require some dy‐
namic movement of either fluid or gas to facilitate preservation. The advantage of these
methods over simple cold storage is that they all have been shown to improve recovery of
donor after cardiac death organs. These organs have the potential to increase the donor pool
by 20–40%.
Figure 4. Illustrative modes of organ preservation. Static or dynamic organ preservation.
7.1. Static organ preservation
Static cold storage (SCS) is the most commonly used preservation method used for all or‐
gans. The principles underlying cold preservation are the slowing of metabolism (by cool‐
ing) and the reduction of cell swelling due to the composition of preservation solutions. The
introduction of the University of Wisconsin (UW) solution by Belzer and Southard for SCS
was a breakthrough and remains the conventional method of preservation. Reduction of
metabolic activity (by cooling) is the major principle of organ preservation [57,58]. At the
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moment the flow of oxygenated blood is terminated, the supply of oxygen, cofactors and
nutrients stops and the accumulation of metabolic waste products begins. Although metabo‐
lism is slowed 1.5- to 2-fold for every 10ºC drop in temperature, anaerobic metabolism con‐
tinues, which leads to depletion of energy stores and concomitant build up of an acidotic
milieu. Depletion of ATP causes loss of transcellular electrolyte gradients, influx of free cal‐
cium and the subsequent activation of phospholipases, and therefore is the main contributor
for cell swelling and lysis. Ischaemia creates the basis for the subsequent production of toxic
molecules after reperfusion, particularly reactive oxygen intermediates, the basis of the cas‐
cade of events that characterize the I/R injury. Even with the most effective preservation sol‐
utions, cold storage aggravates graft injury at the time of transplantation. This situation is
due to two processes, one proportional to the duration of ischemia and the other specifically
related to cooling [57]. Using this preservation method, however, organs undergo injury at
several consecutive stages: warm ischemia prior to preservation, cold preservation injury, is‐
chemic rewarming during surgical implantation and reperfusion injury. With the extension
of criteria to include expanded criteria donor and donation after cardiac death organs, static
preservation is associated with increased delayed graft function and graft loss. In organs re‐
trieved from non-heart-beating donors (NHBD) -with an inevitable period of oxygen depri‐
vation between cardiac arrest and organ perfusion – the deleterious effects of cold ischaemia
are superimposed on the injury sustained during warm ischaemia [57]. Only a few studies
have demonstrated the optimization of graft function and survival with modification of stat‐
ic preservation. It is doubtful that considerable improvements in organ preservation and es‐
pecially in the rescue of marginal organs will be possible as long as the strategy is based on
static principles [58]. In 1990s, Minor et al., developed a new method, called venous system‐
ic oxygen persufflation (VSOP) to supply gaseous oxygen to livers during SCS preservation
[59]. The oxygen was introduced into hepatic vasculature via the suprahepatic vena cava.
This technique was employed on steatotic rat livers for 24 h, and resulting in improved pres‐
ervation of mitochondria and sinusoidal endothelial linings, less KC activation and reduced
hepatocellular enzyme release compared to SCS preservation. Recently, by assessing the en‐
zyme release, energy storage, bile production, and cell death during isolated reperfusion, it
was demonstrated that application of VSOP for 90 minutes may rescue the steatotic livers
after extended (18 h) SCS preservation [60].
7.2. Machine perfusion
Machine liver perfusion is an alternative preservation method to SCS which can be further
categorized based on the temperature employed and has emerged with promising data over
the past decade because it has significant potential in graft preservation and optimization
when the use of marginal organs is the objective. Machine perfusion involves pulsatile per‐
fusion of the liver using a machine as opposed to SCS. This can be performed by perfusing
the liver with a hypothermic perfusate or with a normothermic perfusate. There is experi‐
mental evidence in animal models that machine perfusion protects against liver I/R injury
[61]. The safety and efficacy of machine perfusion compared to SCS to decrease liver I/R in‐
jury is yet to be assessed in humans by randomized controlled trials [61,62].
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Compared with simple cold storage, machine perfusion confers many anticipated advantag‐
es such as the following: 1) provision of continuous circulation and better preservation of
the microcirculation; 2) continuous nutrient and oxygen delivery; 3) removal of metabolic
waste products and toxins; 4) opportunity to assess organ viability; 5) improved clinical out‐
comes via improved immediate graft function rates; 6) prolonged preservation time without
increased preservation damage; 7) administration of cytoprotective and immunomodulating
substances; and 8) lower graft dysfunction incidence, shorter hospital stays, and better graft
survival rates [62].
7.3. Normothermic machine perfusion
In the first half of the 20th century, Alexis Carrel perfused different organs with normother‐
mic, oxygenated serum and demonstrated viability for several days [63]. Actually, the first
successful human LT carried out by Starzl [64], were transplanted after liver graft pretreat‐
ment by machine perfusion with diluted, hyperbaric oxygenated blood. Most perfusion cir‐
cuits were assembled from standard cardiopulmonary bypass components. Principle
constituents are a centrifugal pump, a membrane oxygenator and a heat exchanger. Other
critical components of the perfusate include nutrition (glucose, insulin, aminoacids), drugs
to prevent thrombosis or microcirculatory failure (heparin, prostacyclin) and agents to re‐
duce cellular oedema, cholestasis and free radical injury [57]. Normothermic machine perfu‐
sion (NMP) provides a physiologically-relevant environment to the isolated donor organ,
the quality of liver grafts can be manipulated more efficiently than those simply stored in an
ice-box during SCS, because NMP maintains and mimics normal in vivo liver conditions and
function during the entire period of preservation, thus avoiding hypothermia and hypoxia
and minimizing preservation injury [58,62]. In contrast to cold storage preservation the con‐
cept of normothermic preservation is to maintain cellular metabolism. The underlying prin‐
ciple is the combination of continuous circulation of metabolic substrates for ATP
regeneration and removal of waste products. There is accumulating evidence for the superi‐
ority of the more physiological approach of normothermia in association with an oxygenat‐
ed blood-based perfusion solution [57].
Schön et al., [65] studied NMP to preserve pig livers for transplantation and to rescue them
from warm ischemia in a model of donor after cardiac death. Short (5 h) or prolonged (20 h)
NMP preservation is superior to SCS for normal and ischemically damaged livers, respective‐
ly [62]. The longest preservation of steatotic livers was the NMP preservation for 48 hours in a
pig model by Jamisson et al., who employed blood containing additional insulin and vasodila‐
tors as perfusate, and observed a mild reduction of steatosis from 28% to 15%. The NMP cir‐
cuit dually perfuses 1.5 L of autologous heparinized blood at physiological pressures, which
allows hepatic blood flow autoregulation. Prostacyclin, taurocholic acid, and essential amino
acids are infused continuously. Apart from logistics, one potential drawback of NMP is the
mandatory use of oxygen carriers if blood is not available [62]. Perhaps the only weakness is
that SCS prior to NMP revokes its beneficial effect. Therefore, immediately after cardiac asys‐
tole, normothermic perfusion in the donor should be installed, as described by Fondevila et al.,
[66] for the preservation of livers from uncontrolled donation after cardiac death. The use of
Hepatic Surgery134
NHBDs as a source of liver grafts for transplantation has long been debated. The concept of
normothermic recirculation in the context of NHBDs was first developed by Garcia-Valdeca‐
sas et al., [67]. With 4 h of NMP, hepatic damage incurred during 90 minutes of cardiac arrest
can be reverted, achieving 100% graft survival after 5 days of postransplant follow-up. These
results offer the hope that NMP will be able to increase the clinical applicability of NHBD LT
over that offered by traditional cold storage [67].
Figure 5. Esquematic illustration for ex-vivo and in-vivo normotermic machine perfusion
7.4. Hypothermic machine perfusion
For decades, cooling down organs to cold temperatures allowed successful organ transplan‐
tation within a limited period. The first and most prominent difference between SCS and
(oxygenated) hypothermic machine perfusion (HMP) is the restoration of the tissue’s energy
charge and glycogen content while preventing ATP depletion [62]. In 1990, Pienaar et al.,
[68] reported that seven of eight dogs survived after LT with HMP preservation for 72 h and
a similar outcome after 48 h of SCS. HMP is increasingly being used as an alternative meth‐
od to SCS for the preservation of grafts obtained from nonoptimal donors. Indeed, several
studies have reported a greater reduction in delayed graft function after HMP preservation
than after SCS. Bessems et al., employed HMP preservation with UW-gluconate solution on
steatotic rat livers for 24 h and alleviated I/R compared to SCS [69]. There is a substantial
body of research, predominantly in rodents, demonstrating improved preservation by pro‐
viding oxygen to livers [70]. Nevertheless, clear guidelines towards target values/ranges for
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oxygen levels regarding the optimal duration of oxygenation during HMP are lacking. HMP
can also be applied at the end of the cold storage period, which is attractive for logistical
reasons. The disadvantage here is the time-dependent increase in vascular resistance, bear‐
ing the risk of damage to the sinusoidal endothelium [58].
7.5. Subnormotermic machine perfusion
Subnormothermic machine perfusion (SNMP) preservation lies between HMP and NMP,
but it remained relatively unexplored until recently despite holding promising applications
[71]. In an isolated rat liver perfusion model, SNMP enhanced the functional integrity of
steatotic livers compared with SCS findings. Organ protecting properties mediated by de‐
creasing the temperature to a 20–28ºC have been observed previously. SNMP avoids some
of the downsides of hypothermia while maintaining mitochondrial function and it may cir‐
cumvent the logistical rest raints of NMP [62]. Vairetti et al., preserved steatotic rat livers by
SNMP (20ºC) with Kreb-Henseleit solution for 6 hours and obtained reduced I/R damage
compared to SCS [71].
8. Factors to be considered before the selection of an experimental model
of hepatic I/R
Many investigators have used rodent models of warm (in situ) liver I/R to mimic some of the
pathophysiological events that occur during LT. Although a great deal of useful information
has been generated from these studies, an overriding question remains: Are the mechanisms
responsible for transplant-mediated liver injury and dysfunction the same as those that have
been reported for warm liver I/R injury? The answer is yes and no; that is, some of the mech‐
anisms are similar, but many are dissimilar. It is important to make a distinction between
the different types of ischemia, because there already is some controversy regarding the
pathophysiological mechanisms depending on the type of ischemia (cold or normothermic),
and it should be considered that the type of ischemia, the extent and time of ischemia, the
type of liver submitted to I/R, and the presence of liver regeneration, all lead to differences
in the pathophysiological mechanisms of hepatic I/R. These are discussed below to provide
the reader with a guide to select the appropriate experimental model of hepatic I/R depend‐
ing on the aims being pursued.
8.1. Relevance of the type of surgical procedure
The mechanisms responsible for hepatic I/R injury as well as the effects of pharmacological
treatments are dependently of the liver surgical procedure. There is a range of potentially
conflicting results with regard to the mechanisms responsible for ROS generation in liver I/R
injury depending of the liver surgical procedure evaluated. XDH/XOD system is the main
ROS generator in hepatocytes and LT-related lung damage [72]. However, results obtained
in experimental models of the isolated perfused liver have underestimated the importance
of the XDH/XOD system, and suggest that mitochondria could be the main source of ROS
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[9]. In addition, studies by Metzger et al., in experimental models of normothermic hepatic
ischemia showed that the increased vascular oxidant stress after 30 and 60 minutes of ische‐
mia was attenuated by inactivation of KC but not by high dose of allopurinol in experimen‐
tal models of normothermic hepatic ischemia [73].
It should be considered that the effectiveness of drugs on hepatic regeneration and damage
could be different depending on the surgical conditions evaluated. Thus, gadolinium chlor‐
ide treatment protected against hepatic damage in conditions of I/R without hepatectomy
and improved liver regeneration after PH without I/R [74]. However, the same drug had in‐
jurious effects on hepatic damage and impaired liver regeneration in conditions of PH under
I/R [75]. It should be also considered that the effectiveness of RAS blockers on hepatic regen‐
eration and damage could be different depending on the surgical conditions evaluated. In
conditions of PH under I/R, the AT1R antagonist for nonsteatotic livers and the AT1R and
AT2R antagonists for steatotic ones improved regeneration in the remnant liver. The combi‐
nation of AT1R and AT2R antagonists in steatotic livers showed stronger liver regeneration
than either antagonist used separately and also provided the same protection against dam‐
age as that afforded by AT1R antagonist alone. However, the loss of protection of Ang II re‐
ceptor antagonists against damage in conditions of PH under I/R (only AT1R antagonist
protected steatotic liver against damage) compared with the study of I/R without hepatecto‐
my (in which both Ang-II receptor antagonists reduced damage in both liver types) could be
explained by the different surgical conditions. In the model of I/R without hepatectomy [33],
the blood supply to the left and median liver lobes (70% hepatic mass) was interrupted, and
the other hepatic lobes remained intact. However, in the conditions evaluated herein, only
blood supply to the remnant liver (30% hepatic mass) was interrupted and the other hepatic
lobes were excised. Compared with the study of I/R without hepatectomy [33], in PH under
I/R, there are two main differences, the percentage of hepatic mass that is deprived of blood
supply and hepatic resection. It is well known that the mechanisms of hepatic damage are
different depending on the percentage of hepatic mass that is deprived of blood supply
[76,77]. In addition, the inherent mechanisms of hepatic damage derived from the massive
removal of hepatic mass should be considered. This may explain, at least partially, why the
same drug, such as an Ang II receptor antagonist, may show differential effect on hepatic
injury depending on surgical conditions [36]. In line with this, clinical and experimental
studies revealed the injurious effects of NO on damage in the remnant liver in conditions of
PH under I/R [36]. However NO protect against hepatic damage in an experimental model
of I/R without PH [11]. In PH under I/R, Ang-II is an appropriate therapeutic target to pro‐
tect steatotic livers against hepatic damage and regenerative failure. However, this target
could be not appropriate in steatotic LT, since the results indicate a novel target for thera‐
peutic interventions in LT within the RAS cascade, based on Ang 1-7, which could be specif‐
ic for this type of liver. Indeed, Ang 1-7 receptor antagonist reduced necrotic cell death and
increased survival in recipients transplanted with steatotic liver grafts [15].
The results, based on isolated perfused liver, indicated that the addition of epidermal
growth factor (EGF) and isulin-like growth factor 1 (IGF-I) separately or in combination to
UW reduced hepatic injury and improved function in both liver types. EGF increased IGF-I,
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and both additives up-regulated AKT in both liver types. This was associated with glycogen
synthase kinase-3β (GSK3β) inhibition in non-steatotic livers and PPARγ over-expression in
steatotic livers [78]. The benefits of EGF and IGF-I as additives in UW solution were also
clearly seen in an experimental model of normothermic hepatic ischemia. However, the rela‐
tionship between EGF and IGF-I was different dependently of the surgical procedure. In‐
deed, under these conditions, IGF-I increased EGF, thus protecting steatotic and non-
steatotic livers against I/R damage. The beneficial role of EGF on hepatic I/R damage may be
attributable to p38 inhibition in non-steatotic livers and to PPARγ overexpression in steatot‐
ic livers [79].
PPARα agonists as well as ischemic preconditioning (IP), through PPARα, inhibited mito‐
gen-activated protein kinase expression following I/R in steatotic livers undergoing normo‐
thermic hepatic ischemia. This in turn inhibited the accumulation of adiponectin in steatotic
livers and reduced its negative effects on oxidative stress and hepatic injury [13]. In line
with this, adiponectin silent small interfering RNA (siRNA) treatment decreased oxidative
stress and hepatic injury in steatotic livers. However, another study by Man et al., 2006 [80]
in small fatty grafts, adiponectin treatment exerted anti-inflammatory effects that down-
regulated TNFα mRNA and vasoregulatory effects that improved the microcirculation. Adi‐
ponectin anti-inflammatory effects also include the activation of cell survival signaling via
the phosphorylation of Akt and the stimulation of NO production. Additionally, the studies
by Man et al., [80] showed the anti-obesity and proliferative properties of adiponectin in
small fatty transplants. Taken together, the aforementioned data indicate that the action
mechanisms of adiponectin depend on the surgical conditions. Thus, on the basis of the dif‐
ferent results reported to date in hepatic I/R, it is difficult to discern whether we should aim
to inhibit adiponectin, or administer adiponectin to protect steatotic livers against cold is‐
chemia associated with transplantation. Moreover, the adiponectin data reported for these
experimental models of hepatic I/R [13,80] should not be extrapolated to cadaveric organ
transplantation. For small liver grafts (which are relatively common) and under conditions
of warm ischemia, the periods of ischemia range from 40 to 60 minutes; this range may not
be accurate for cadaveric donor LT.
RBP4 is an adipokine synthesized by the liver, whose known function is to transport retinol
in circulation. However, the role of RBP4 in hepatic I/R could depend on the liver surgical
procedure. Steatotic liver grafts were found to be more vulnerable to the down-regulation of
RBP4. RBP4 treatment-through AMP-activated protein kinase (AMPK) induction- reduced
PPARγ over-expression, thus protecting steatotic liver grafts against I/R injury associated
with transplantation. In terms of clinical application, therapies based on RBP4 treatment and
PPARγ antagonists might open new avenues for steatotic LT and improve the initial condi‐
tions of donor livers with low steatosis that are available for transplantation [81]. On the oth‐
er hand, the effects of RBP4 could depend on the surgical conditions. Indeed, RBP4
administration not only failed to protect both liver types from damage and regenerative fail‐
ure, it exacerbated the negative consequences of liver surgery in PH under I/R [82]. Under
these conditions, RBP4 affected the mobilization of retinol from steatotic livers, revealing ac‐
tions of RBP4 independent of simple retinol transport. The injurious effects of RBP4 were
Hepatic Surgery138
not due to changes in retinol levels. Thus, strategies based on modulating RBP4 could be in‐
effective and possibly even harmful in both liver types in PH under I/R or surgical condi‐
tions including small-for-size LT.
8.2. Relevance of the duration of hepatic ischemia
The severity of hepatocyte damage depends on duration of ischemia. Depending on the ob‐
jectives of the research, it is important to consider a specific ischemia duration. In other
words, if you want to study the mechanisms involved in hepatic I/R injury or the protective
mechanisms of a drug, it is more appropriate to use a duration of ischemia associated with
high survival. If the purpose is to study the relevance of a drug in hepatic I/R injury, then it
is advisable to assess survival, and, therefore, it is more adequate to use experimental mod‐
els in which the ischemic period is associated with low survival. These observations are
based on the following data reported in the literature. It appears that short periods (60 mi‐
nutes) of warm ischemia result in reversible cell injury, in which liver oxygen consumption
returns to control levels when oxygen is resupplied after ischemia. Reperfusion after more
prolonged periods of warm ischemia (120-180 minutes) results in irreversible cell damage.
These observations agree with a previous report on rat liver subjected to I/R, indicating a
cellular endpoint for hepatocytes after 90 minutes of ischemia [83]. In human LT, a long is‐
chemic period is a predicting factor for posttransplantation graft dysfunction, and some
transplantation groups hesitate to transplant liver grafts preserved for more than 10 h. Some
studies in experimental models of LT indicate that cold ischemia for 24 h induces low sur‐
vival. However, LT, following shorter ischemic periods, may also result in primary organ
dysfunction [72].
It is important to distinguish between the types of Ischemia (warm and cold) because there
is already some controversy about the pathophysiological mechanisms of cold ischemia,
which may depend, for example, on the time. The mechanisms of hepatic I/R injury are also
different depending on the duration of hepatic ischemia. Along these lines, in the same ex‐
perimental model of LT, XDH/XOD plays a crucial role in hepatic I/R injury only in condi‐
tions under which significant conversion of XDH to XOD occurs (80–90% of XOD) such as
16 h of cold ischemia. However, this ROS generation system does not appear to be crucial
for shorter ischemic periods such as 6 h of cold ischemia [72]. Similarly, it should also be
noted that oxidative stress in hepatocytes and the stimulatory state of KCs after I/R depend
on the duration of ischemia and may also differ between ischemia at 4ºC and that at 37ºC,
which probably leads to different developmental mechanisms of liver damage.
Our previous results indicate that PPARα does not play a crucial role in I/R injury in non‐
steatotic livers. This contrasts with a study published by Okaya and Lentsch [84], in which
the authors reported the benefits of PPARα agonists on postischemic liver injury. Although
the dose and pretreatment time of the PPARα agonist WY-14643 were similar in both stud‐
ies, Okaya and Lentsch reported an ischemic period of 90 minutes; ours was 60 minutes,
which is the ischemic period currently used in liver surgery [3]. Thus, 60 minutes of ische‐
mia seems to be insufficient to induce changes in PPARα in nonsteatotic livers [13].
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8.3. Relevance of the extent of hepatic ischemia
Another factor to consider before selecting the experimental model of hepatic I/R is the per‐
centage of hepatic ischemia applied. The extent of hepatic injury as well as the hepatic I/R
mechanisms, including the recovery of blood flow and energy charge during hepatic reper‐
fusion is dependent on the extent of ischemia-whether total or partial (70%) hepatic ische‐
mia is applied [36]. This fact could be explained by the stealing phenomenon. In contrast to
100% hepatic ischemia, during ischemia in the left and median lobes, the flow is shunted via
the right lobes and following the release of the occlusion of the left and median lobes, a sig‐
nificant amount of shunting via the right lobes will continue during reperfusion until vascu‐
lar resistance in the postischemic lobes decreases. This occurs because blood flows through
the path of least resistance. The reasons for this may be cellular swelling endothelial, stasis,
or other changes. Thus, the recovery of blood flow and hepatic perfusion of the preischemic
lobe is later in the case of 70% hepatic ischemia than in 100% hepatic ischemia [76]. In line
with these observations, the benefits of some drugs such as ATP-MgCl2 were dependent on
the extent of hepatic ischemia used [32,77].
8.4. Relevance of the type of liver submitted to I/R
A variety of clinical factors including starvation, graft age, and steatosis have been studied
in different experimental models of hepatic I/R because of the relevance of these factors in
clinical practice. These factors enhance liver susceptibility to I/R injury, further increasing
the patient risks related to reperfusion injury.
8.4.1. Starvation
The pre-existent nutritional status is a major determinant of the hepatocyte injury associated
with I/R. In clinical LT, starvation of the donor, due to prolonged intensive care unit hospi‐
talization or the lack of adequate nutritional support, increases the incidence of hepatocellu‐
lar injury and primary nonfunction [85]. Based on the nutritional state status, several
experimental and clinical studies support the hypothesis that the availability of glycolytic
substrates is important for maintenance of hepatic ATP levels during I/R. Fasting exacer‐
bates I/R injury because the low content of glycogen stores results in more rapid ATP deple‐
tion during ischemia. In addition, fasting causes alterations in tissue antioxidant defenses,
accelerates the conversion of XDH to XOD during hypoxia and induces mitochondrial alter‐
ations [85]. Caraceni et al., [86] have shown that mitochondrial damage is greatly enhanced
by fasting which decreases the hepatic content of antioxiants and therefore sensitizes the mi‐
tochondrial to the injurious effects of ROS. Considering these observations, an artificial nu‐
tritional support may represent a new approach for the prevention of reperfusion injury in
fasted livers. On the contrary, fasting has been reported to improve organ viability and sur‐
vival [87], as it reduces phagocytosis and the generation of TNF-α [87]. To understand these
apparent contradictory results, it is important to consider the different experimental condi‐
tions in these investigations. A beneficial effect of high glycogen content can mainly be ex‐
pected under conditions of long preservation times and long periods of warm ischemia.
Under these conditions, high metabolic reserves of the liver may attenuate ischemic cell in‐
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jury and preserve defense functions against cytotoxic mediators of KCs. Conversely, short
ischemic periods require lower metabolic reserves, and the extent of KC activation can be
the dominant factor in early graft injury.
8.4.2. Age
A number of distinct age-related alterations have been identified in the hepatic inflammato‐
ry response to hepatic I/R [88]. Under warm hepatic ischemia, mature adult mice had great‐
ly increased neutrophil function, increased intracellular oxidant levels, and decreased
mitochondrial function compared with the findings in young adult mice. These alterations
contributed to the increased liver injury after I/R observed in mature adult mice compared
with that in young adult mice. The results obtained in an experimental model of isolated
perfused liver indicate that, during reperfusion, livers obtained from old rats generate a
lower amount of oxyradicals than livers from young rats. This fact could be explained by the
lower KC activity, the reduction of liver blood flow, and the impaired functions and struc‐
tural alterations observed in the livers of old rats. In fact, in hepatocytes from mature adult
mice, delayed activation of nuclear factor kappa B (NFκB) in response to TNF-α and virtual‐
ly no production of macrophage inflammatory protein 2 have been detected, which may be
due to an agerelated defect in hepatocytes [88].
8.4.3. Steatosis
The first step to minimize the adverse effects of I/R in steatotic livers is a full understanding
of the mechanisms involved in I/R injury in these marginal organs. This can be achieved on‐
ly with the selection of an appropriate method to induce steatosis in livers undergoing I/R. It
is well known that the mechanisms involved in hepatic I/R injury are different depending
on the type of liver (nonsteatotic versus steatotic livers). In addition to the impairment of
microcirculation, mitochondrial ROS generation dramatically increases during reperfusion
in steatotic livers [9,86]. Results obtained under warm hepatic ischemia indicate that apopto‐
sis is the predominant form of hepatocyte death in the ischemic nonsteatotic liver, whereas
the steatotic livers develop massive necrosis after an ischemic insult [9]. Steatotic livers dif‐
fered from nonsteatotic livers in their response to the UPR and ER stress since IRE1 and
PERK were weaker in the presence of steatosis [89]. Decreased ATP production and dys‐
function of regulators of apoptosis, such that Bcl-2, Bcl-xL and Bax have been proposed to
explain the failure of apoptosis in steatotic livers. Differences were also observed when we
analyzed the role of the RAS, as the nonsteatotic grafts exhibited higher Ang-II levels than
steatotic grafts whereas steatotic grafts exhibited higher Ang 1-7 levels [15]. In the context of
I/R injury associated with LT, the axis ACE-Ang II-ATR and ACE2-Ang 1-7-Mas play a ma‐
jor role in nonsteatotic and steatotic grafts, respectively. From the point of view of clinical
application, these findings may open up new possibilities for therapeutic interventions in LT
within the RAS cascade, based on Ang 1-7 for steatotic livers and Ang II for non-steatotic
ones [15]. Moreover, reduced RBP4 and increased PPARγ levels were observed in steatotic
livers compared to non-steatotic livers [81]. The vulnerability of steatotic livers subjected to
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warm ischemia is also associated with increased adiponectin, oxidative stress, and IL-1 lev‐
els and a reduced ability to generate IL-10 and PPARα [13,90].
It should be considered that there are differences in the mechanisms involved in hepatic I/R
injury depending on the method used to induce steatosis. In contrast with other experimen‐
tal models of steatosis, both dietary high fat and alcohol exposure induced the production of
SOD/catalase-insensitive ROS, which may be involved in the mechanism of steatotic liver
failure after OLT [9]. Neutrophils have been involved in the increased vulnerability of stea‐
totic livers to I/R injury, especially in alcoholic steatotic livers. However, neutrophils do not
account for the differentially greater injury in non-alcoholic steatotic livers during the early
or late hours of reperfusion. Similarly, the role of TNF in the vulnerability of steatotic livers
to I/R injury may be dependent on the type of steatosis [1,9].
8.5. Relevance of regeneration in experimental models of hepatic I/R
It is known that different experimental models trigger different responses when a common
mechanism or the same drug is investigated. This situation is witnessed when analyzing liv‐
er injury in models of I/R with or without hepatectomy. This situation is illustrated by Ram‐
alho et al., [36] regarding the loss of protection of Ang-II receptor antagonists against liver
damage in conditions of PH under I/R compared with the study of I/R without hepatectomy,
in which Ang-II receptor antagonists reduced hepatic damage. These different results could
not be explained by differences in the dose or frequency of drug administration but rather
by differences in surgical conditions (percentage of hepatic ischemia and the presence or ab‐
sence of hepatectomy). In the model of I/R without hepatectomy [33], the blood supply to
the left and median liver lobes (70% hepatic mass) was interrupted, and the other hepatic
lobes remained intact. However, in PH under I/R, only blood supply to the remnant liver
(30% hepatic mass) was interrupted and the other hepatic lobes were excised [36].
According to the cell type and experimental or pathologic conditions, TNF-α may stimu‐
late cell  death or it  may induce hepatoprotective effects  mediated by antioxidant,  antia‐
poptotic,  and  other  anti-stress  mediators  coupled  with  a  pro-proliferative  biologic
response. For example, although the deleterious effect of the TNF-α in local and systemic
damage associated with hepatic I/R in experimental  models of  normothermic hepatic is‐
chemia is well established [91], this mediator is also a key factor in hepatic regeneration
[92], an important process in RSLT and PH associated with hepatic resections [93]. These
differential effects observed for TNF-α can also be extrapolated to transcription factors. It
is  well  known that  NFκB can regulate  various downstream pathways and thus has  the
potential to be both pro- and antiapoptotic [8]. Currently it is not clear whether the bene‐
ficial  effects  of  NFκB activation in protection against  apoptosis  or  its  detrimental  proin‐
flammatory  role  predominate  in  liver  I/R  [8].  Hepatic  neutrophil  recruitment  and
hepatocellular  injury  are  significantly  NFκB  activation  is  suppressed  in  mice  following
partial hepatic I/R. However, NFκB activation is essential for hepatic regeneration after rat
LT, and reduces apoptosis and hepatic I/R injury [94].
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9. Strategies applied in experimental models of hepatic I/R
9.1. Pharmacological treatment and additives in preservation solution
Numerous experimental studies have focused on the developing in vivo  pharmacological
strategies  aimed at  inhibiting the harmful  effects  of  I/R [9,72,89,90,95-99].  Some of  these
studies are summarized in Table 1.  However,  none of  these treatments has managed to
prevent hepatic I/R injury. A large number of ingredients-which have been introduced in‐
to UW solution in experimental models of hepatic cold ischemia [9,95,100-102] (Table 1).
However, none of these modifications to the UW solution composition have found their
way into routine  clinical  practice.  Further  studies  will  be  required to  elucidate  whether
the use of perfluorochemicals (PFC) in preservation solutions might improve the viability
of liver grafts  undergoing transplantation.  PFC are hydrocarbons with high capacity for
dissolving respiratory and other nonpolar gases. A negligible O2-binding constant of PFC
allows them to release O2  more effectively than hemoglobin into the surrounding tissue
(acts as an oxygen-supplying agent). PFC differs from hemoglobin preparations in that it
is  a  totally synthetic  compound formed on a liquid hydrocarbon base.  Unlike hemoglo‐
bin, acidosis, alkalosis, and temperature seem to have no or little effect on the oxygen de‐
livery  of  PFC,  allowing  this  compound  to  be  used  effectively  during  cold  storage  of
organs [103]. A recently study, used Oxycyte, a PFC added to UW solution can be benefi‐
cial  after  cardiac  death liver  graft  preservation in  a  rat  model  [103].  However,  their  ef‐
fects on reperfusion injury were not evaluated in that study. In fact,  the possibility that
preoxygenated  PFC  exacerbates  the  ROS  during  reperfusion  should  not  be  discarded
since the use of gaseous oxygen applied to the livers during the storage period was only
effective in improving hepatic viability upon reperfusion when antioxidants were added
to the UW rinse solution [104].
It should be also considered that the inclusion of some components in the UW solution has
been both advocated and criticized. Indeed, simplified variants of the UW solution in which
some additive were omitted were demonstrated to have similar or even higher protective
potential during cold liver storage. Another limitation of the UW solution is that some of its
constituent compounds, including allopurinol do not offer very good protection because
they are not present at a suitable concentration and encounter problems in reaching their
site of action [9]. The possible side effects of some drugs may frequently limit their use in
human LT. For example, idiosyncratic liver injury in humans is documented for chlorpro‐
mazine, pernicious systemic effects have been described for NO donors, allopurinol therapy
can cause hematological changes and gadolinium can induce coagulation disorders. Some
case reports of acute hepatotoxicity attributed to rosiglitazone have been published [105].
The development of therapeutic strategies that utilize the protective effect of heme oxygen‐
ase-1 induction is hampered by the fact that most pharmacological inducers of this enzyme
perturb organ function by themselves [106].
Pharmacological  treatment-derived  difficulties  must  also  be  considered.  In  this  regard,
SOD and GSH exhibit inadequate delivery to intracellular sites of ROS action [9]. The ad‐
ministration of anti-TNF antibodies does not effectively protect against hepatic I/R injury,
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and this finding has been related to the failure of complete TNF-α neutralization locally
[11].  Although this  also occurs  in  non-steatotic  livers,  modulating I/R injury in steatotic
livers  poses  a  greater  problem.  Differences  in  the  action  mechanisms  between  steatotic
and non-steatotic livers mean that therapies that are effective in non-steatotic livers may
prove useless in the presence of steatosis, and the effective drug dose may differ between
the two liver types. Findings such as these must be considered when applying pharmaco‐
logical strategies in the same manner to steatotic and non-steatotic livers because the ef‐
fects may be very different. For example, caspase inhibition, a highly protective strategy
in non-steatotic livers, had no effect on hepatocyte injury in steatotic livers [9]. Moreover,
whereas in an LT experimental model, an NO donor reduced oxidative stress in non-stea‐
totic livers, the same dose increased the vulnerability of steatotic grafts to I/R injury. Fur‐
thermore, there may be drugs that would only be effective in steatotic livers. This was the
case of compounds such as cerulenin, which reduce UCP-2 expression in steatotic livers
and carnitine [9].




Mice Cerulenin (Fatty acid synthase
inhibitor) 15 min




Apocynin (NAPH oxidase inhibitor) ↓ Oxidative stress
TBC-1269 (Pan-selectin antagonist) 90 min ↓ Inflammatory response, ERK ½
Rat
Rat
Lisinopril  (ACE inhibitor)
30 min
↓ Oxidative stress
Ascorbate (ROS scavenger) ↓ Apoptosis
Allopurinol (XOD inhibitor) 30 60 min ↓Oxidative stress
Melatonin (Hormone) 40 min ↓ IKK, JNK pathways
SOD (antioxidant)
45 min
↓ Microcirculatory disturbances, leukocyte
acumulation
L-arginine (NO precursor) ↑ NO, ATP ↓ Neutrophil accumulation




↓ IL-1, Oxidative stress
Anti-ICAM-1 ↓ Adherence of leukocytes in postsinusoidal venules
Gabexate mesilate (Protease
inhibitor)
↓ TNF-α, Leukocyte activation
OP-2507 (Analogue of prostacyclin) ↓ Microcirculatory disturbance
WY-14643 (PPARα agonist) ↓ Oxidative stress, Inflammatory cytokines
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n-3 PUFA ↓ Liver injury, Oxidative stress
Glutathione (Antioxidant)
60 90 min
↓ Microcirculatory disturbances ↑ Detoxification of
ROS
Spermine NONOate (NO donor) ↓ IL-1α, Oxidative stress
FK506 (Immunosupressant) ↓ TNF





Anti-TNF antiserum ↓ TNF, Leukocyte accumulation
α-Lipoic acid (Antioxidant) ↑ Liver regeneration, ↓ Apoptosis






↓ Endoplasmic reticulum stress
Sirolimus (Immunossupressant) ↓ Linfocytes
IL-1ra (IL-1 receptor antagonist) 90 min ↓ TNF, Oxidative stress
Dog FK 3311 (Cox-2 inhibitor) 60 min ↓ Neutrophil infiltration, Cox-2




Mice Cerulenin (fatty acid synthaseinhibitor) 80 min
↓ UPC2, ↑ ATP
Rat FK 409 (NO donor) 80 min ↑ HSP, IL-10, ↓ SEC damage, IL-1
CS1 peptides (FN-α4β1 interac
blocker) 4 h
↓ Neutrophil and lymphocyte T infiltration, TNF-α,
iNOS






↓ Macrophages infiltration and T cells
PSGL-1 (P-selectin blocker) ↓ Neutrophil infiltration, TNF-α, INFγ, iNOS
Anti-TNF antiserum 6, 24 h ↓ TNF, Leukocyte accumulation
SOD (antioxidant)
8 h
↓ Microcirculatory disturbance, Leukocyte acumulation
Tauroursodeoxycholate (Bile acid) ↓ Endoplasmic reticulum stress
Allopurinol (XOD inhibitor) 8, 16 h ↓Oxidative stress
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Z-DEVD-FMK (caspase 3 and 7
inhibitor) 16 h
↑ Microvascular perfusión, Bcl-2 ↓ Apoptosis
L-arginine (NO precursor)
18 h
↑ NO, ATP, ↓ Neutrophil accumulation
Treprostinil (Prostacyclin analogue) ↓ Liver injury, Platelet deposition, microcirculatorydisturbance
ANP (vasodilating peptide)
24 h
↑ PI3K/Akt, ↓ Apoptosis
Bucillamine (antioxidant) ↓Oxidative stress
Chlorpromazine (Ca2 + channel
antagonist)
↑ ATP ↓ Mitocondrial dysfunction, Alterations in lipid
metabolism
sCR1 (complement inhibitor) ↓ Microcirculatory disturbance, Leukocyte adhesion




Anti-ICAM-1 ↓ Adherence of leukocytes in postsinusoidal venules
Glycine (Kupfer cell modulator) ↓ Neutrophil accumulation, TNF-α
GdCl3 (Kupffer cell blocker) ↓ Neutrophil accumulation, TNF-α
Cbz-Val-Phe methyl ester (calpain
inhibitor)
24, 40h ↓ Calpain activation, SEC apoptotic
EHNA (adenosine deaminase
inhibitor)
24, 44 H ↑ Interstitial adenosine ↓ Microcirculatory disturbance,
Leukocytes rolling
CGS-21680 (adenosine A2 receptor
agonist)
30 h ↑ cAMP, ↓ SEC Killing
Sotrastaurin (PKC Inhibitor) ↓ Apoptosis, macrophage/neutrophil accumulation
FR167653 (IL-1β and TNF-α supressor) 48 h ↓ TNF-α, IL-1α, Kupffer cell activation
Doxorubicin (Heat shock proteins
inducer)
↓ TNF-α, MIP-2, NKκB
Pig Sodium ozagrel (Thromboxanesynthase inhibitor)
8 h ↓ ET-1




Mouse Erythropoietin (EPO) 24 h ↓ Liver injury
Rat Meloxicam (COX-2 Inhibitor) 1 h ↓ Apoptosis, Liver injury, Oxidative stress
Simvastatin (KLF2-inducer) 1, 6, 16 h ↓ Inflammation, Liver injury, Oxidative stress,
Tauroursodeoxycholate (Bile acid) 2 h ↓ Endoplasmic reticulum stress
S-nitroso-N-acetylcysteine 2, 4, 6 h ↓ Liver injury
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LY294002 (PI3K inhibitor) 7, 9, 24 h ↓ Apoptosis
8br-cAMP, 8br-cGMP (nucleotide
analogs)
24 h ↓ TNF-α and neutrophil accumulation
Ruthenium red (mitochondrial Ca2+
uniporter inhibitor) ↓ Mitocondrial dysfunction
Melatonin (Hormone) ↓ Oxidative stress, Liver injury
OP-4183 (PGI2 analogue) ↓ Oxidative stress
SAM (ATP precursor) ↓ Oxidative stress
IDN-1965 (caspase inhibitor) 24, 30 h ↓ Apoptosis
Pifithrin-alpha (p53 inhibitor) 24, 48 h ↓ Apoptosis
Sodium nitroprusside (NO donor) ↓ Microcirculatory dysturbances
FR167653 (p38 inhibitor) 30 h ↓ Microcirculatory dysturbances
GSNO (NO donor) 48 h ↓ SEC damage
Dog Trifluoperazine (calmodulin inhibitor) 24 h ↓ Microcirculatory dysturbances
Pig
E5880 (PAF antagonist) 8 h ↓ Microcirculatory dysturbances
EGF, IGF-1, NGF-α 18 h ↑ ATP
Table 1. In vivo pharmacological therapy and additives in preservation solution in experimental models of warm
hepatic ischemia (with or whithout hepatectomy) and liver transplantation
9.2. Gene therapy
Advances in molecular biology provide new opportunities to reduce liver I/R injury by us‐
ing gene therapy. Genome manipulation can be achieved by: A) germ line manipulation (oo‐
cyte  injections);  B)  stem  cell  transformation  and  reintroduction  into  embryos,  and  C)
targeting specific  cells  or  organs  with  vectors  or  viruses  (gene transfer).  The first  2  ap‐
proaches include germ-line alterations and are neither feasible nor accepted by society. The
third approach would lend to the treatment of individual patients with either acquired or
congenital diseases [12]. In the last years, significant advances in gene therapy vectors have
occurred. Gene transfer can be accomplished by direct injection of DNA into a target or‐
gan or tissue, transduction by recombinant viral vectors carrying a specific gene of inter‐
est,  e.g.,  adenovirus  (Ad)  or  retrovirus,  transfection  of  cells  by  chemical  methods  (e.g.,
cationic liposomes), or stem cell transduction and reintroduction of genetically-altered cells
back into embryos [107] (Table 2). Currently, researchers in gene transfer have focused ef‐
forts toward targeting vectors to specific cells or organs without loss of transduction abili‐
ty  [108,109],  allowing  high  level  gene  transduction  of  the  liver  without  affecting  other
organs [12,107].






















Oncoretrovirus RNA 9 kb Long Yes Low
Lentivirus RNA 10 kb Long Yes Low
Foamy RNA 12 kb Long No High
Herpes virus DNA "/>30 kb Transient No High
Adenovirus DNA 30 kb Transient Rarely Moderate
AAV DNA 4.6 kb Long postmitotictissues Rarely Moderate
Oncoretrovirus RNA 9 kb Long Yes Low







s siRNA RNA No limitation Transient No Zero
DNA injection DNA No limitation Transient No Zero
Cationic liposomes DNA No limitation Transient No Zero
Stem cell
transduction DNA No limitation Transient No Zero
Table 2. Summary of gene therapy vectors commonly used.
Antiapoptotic Strategies (Bcl-2/Bcl-Xl, Bag-1 and caspases): Bcl-2 blocks apoptosis and necrosis
and has been implicated in the prolongation of cell survival [110]. Given its functional impor‐
tance in the cell death cascade, it constitutes one of the key targets for cytoprotective therapeu‐
tic manipulation for the regulation of apoptosis [110,111]. As demostrated by Bilbao et al., [111]
in a mouse hepatic I/R model, overexpression of Ad-mediated Bcl-2 gene significantly de‐
creased hepatocyte apoptosis and necrosis, improved hepatic function, and prolonged surviv‐
al as compared with controls. In addition, Bag-1 is a Bcl-2 binding protein resulting in a
prolonged and stabilized antiapoptotic activity [112]. In addition, Bag-1 appears to exert an in‐
direct silencing effect on TNF receptor R1 and hence suppresses the death receptor signal. A re‐
cent study by Sawitzki et al., [113] has demonstrated the cytoprotective effect of Ad-mediated
Bag-1 gene transfer in rat liver I/R. Using a model of cold ischemia and OLT, Ad-Bag-1 trans‐
fer improved portal venous blood flow, increased bile production, and improved hepatic func‐
tion with decreased neutrophil accumulation in the graft. Furthermore, Ad-mediated Bag-1
expression preserved hepatic architecture and reduced inflammation. The activation of T cells
infiltrating the graft was inhibited, since decreased expression of TNF-α, CD25, IL-2, and IFNγ
[107]. Caspase-8 is presumed to be the apex of the death-mediated apoptosis pathway, where‐
as caspase-3 belongs to the “effector” proteases in the apoptosis cascade. Contreras et al., dem‐
onstrated that inhibition of caspase-8 and caspase-3 by siRNA provided significant protection
against warm hepatic I/R injury and decreased animal mortality. In addition, animals given
siRNA caspase-8, or more significantly siRNA caspase-3, presented lower neutrophil infiltra‐
tion and better histologic profiles [114].
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Antioxidant therapy (SOD, HO-1, Ferritin): Oxidative stress can activate NF-κB and the AP-1
pathway and induce expression of proinflammatory genes including cytokines, adhesion
molecules, and chemokines leading to neutrophil-mediated inflammation [115-117]. To in‐
hibit the burst of ROS or its effect on hepatocytes, several oxygen stress inhibitory proteins
have been studied, e.g., SOD and catalase have been transfected by either adenovirus, lipo‐
somes or polyethylene-glycol [8,12,118]. Using partial hepatic I/R models, Ad-mediated
MnSOD administration reduced liver tissue damage and activation of both NF-κB and AP1
[119,120] when compared with lacZ-transduced controls. In another study, He et al., [121]
demonstrated that SOD or catalase gene delivery by polylipid nanoparticles injected via the
portal vein 1 day prior to the warm I/R procedure resulted in high levels of the transgene
enzyme activity in the liver, and markedly attenuated hepatic I/R injury [121]. However, re‐
sults with NFκB activation have been conflicting. Takahashi et al. reported that overexpres‐
sion of IκB, an NFκB inhibitor (mediated by Ad-IκB) resulted in partial protection in hepatic
I/R injury [122]. Heme oxygenase 1 (HO-1) is a stress responsive protein and can be induced
by various conditions such as hypoxia [12,107]. Several studies have shown that HO-1 ex‐
hibits potent cytoprotective effects after hepatic I/R [123,124]. In a cold ex-vivo rat liver per‐
fusion model and a syngeneic liver transplant OLT model, treatment of genetically obese
Zucker rats with Ad-HO-1 improved portal venous blood flow, increased bile production,
and decreased hepatocyte injury [123]. Unlike in untreated rats, upregulation of HO-1 corre‐
lated with preserved hepatic architecture, improved liver function, and depressed infiltra‐
tion by T cells and macrophages. Ad-mediated HO-1 gene overexpression increased
survival of recipients from 40% to 80% [12,107]. Ad-HO-1 gene transfer decreased macro‐
phage infiltration in the portal areas and inducible nitric oxide synthetase (iNOs) expres‐
sion; it also increased the expression of antiapoptotic genes Bcl-2/Bcl-xl and Bag-1, as
compared with controls [107]. Iron chelation is another approach to ameliorate the I/R injury
cascade. Free iron has been shown to play a role in the formation of the free radicals through
the Fenton reaction; these contribute to endothelial cell damage. Ferritin induction is a result
of the action of HO-1 on the heme porphyrin causing the release of Fe2+. Ferritin can reduce
the availability of intracellular free Fe2+, which can participate in free radical generation
[125]. Studies by Ke et al., [107] demostrated that overexpression of Ad vector carrying the
ferritin heavy chain (H-ferritin) gene protects rat livers from I/R injury [126]. In these stud‐
ies, the protective effect of H-ferritin was associated with the inhibition of endothelial cell
and hepatocyte apoptosis. Evidence suggested that H-ferritin exerts an antiapoptotic role
and may be used as a therapeutic measure to prevent I/R [107].
Immunoregulatory cytokines (IL-10 and IL-13) and IL-1 receptor antagonist (IL-1R): IL-13 regu‐
lates liver inflammatory I/R injury via the signal transducer and activator of transcription 6
(STAT6) pathway [127]. IL-10 induces antioxidant HO-1 gene expression in murine macro‐
phages and exerts anti-inflammatory effects [128]. In recent studies, Ad-IL-13 gene transfer
in cold ischemia models has shown powerful cytoprotective effects [129]. Gene transfer of
IL-13 improved hepatic function, upregulated HO-1, and prevented hepatic apoptosis
through the upregulation of Bcl-2/Bcl-xl [107]. The beneficial effects of IL-13 correlated with
in vivo cross talk between innate TLR4 and adaptive Stat6 immunity [130]. In fact, using an
experimental model of warm hepatic ischemia, Stat6-deficient mice with Ad-IL-13 failed to
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improve hepatic function and hepatic histological features. Transfer of Ad-IL-13 increased
anti-oxidant HO-1 expression and inhibited TLR4 activation in WT mice, whereas low HO-1
and enhanced TLR4 expression was shown in Stat6-deficient mice [107]. It has been demon‐
strated that the pro-inflammatory cytokine IL-1 plays a critical role in the pathophysiologi‐
cal response to I/R. Experimental results have shown that blockade of the IL-1R reduced
TNF production and liver damage [131]. In a partial hepatic I/R model, gene transfer of Ad-
mediated IL-1R antagonist prolonged animal survival and improved hepatic function while
preserving the histological architecture. In addition, a marked decrease in production of
proinflammatory cytokines such as IL-1, TNF-α, and IL-6 was present [107].
T-cell co-stimulation blockade: CD40-CD154. A number of studies have shown that CD4+ T
lymphocytes play an important role as key cellular mediators in I/R injury mediated inflam‐
matory responses. The CD40–CD154 co-stimulation pathway provides the essential second
signal in the initiation and maintenance of T-cell-dependent immune esponses [132]. Recent
studies have demonstrated that CD40-CD154 is required for the mechanism of hepatic
warm I/R injury [133]. In OLT, prolonged in vivo blockade of the CD40-CD154 interaction
following pretreatment of liver isografts with Ad-CD40Ig exerted potent cytoprotection
against I/R injury. Apoptosis was prevented and neutrophil accumulation was reduced. Evi‐
dence also demonstrated prevention of Th1-type cytokine (interferon γ (IFN-γ) and IL-2)
upregulation and the local expression of antioxidant HO-1 and antiapoptotic Bcl-2/Bcl-xl
genes were triggered [107].
Adipocytokine, sphyngolipid and TLR4 regulation: Massip-Salcedo et al., [13] demostrated
though the systemic delivery of adiponectin in livers treated with adiponectin siRNA that
steatotic livers by themselves can generate adiponectin as a consequence of I/R. This study
reports evidence of the injurious effects of adiponectin in stetatotic livers under warm ische‐
mic conditions, and results suggest the clinical potential of gene therapy for I/R damage in
steatotic livers by siRNA-mediated adiponectin gene silencing [13]. Products of sphingolipid
metabolism are important second messengers that regulate a variety of cell processes includ‐
ing cell death, proliferation, and inflammation. Using a mice warm hepatic I/R model, Shi et
al., demonstrated that SK2 knockdown by siRNA effectively prevented hepatocyte death
[134]. Jiang et al., [135] reported a hepatocyte-specific delivery system for the treatment of
liver I/R, using galactose-conjugated liposome nanoparticles (Gal-LipoNP). Heptocyte-spe‐
cific targeting was validated by selective in vivo delivery as observed by increased Gal-Lip‐
oNP accumulation and gene silencing in the liver. Gal-LipoNP TLR4 siRNA treatment
reduced hepatic damage, neutrophil accumulation and the inflammatory cytokines IL-1 and
TNF-α [135].
Advances in molecular biology have provided new opportunities to reduce liver I/R injury
using gene therapy [9,12,13,96,114] (Table 3). However, the experimental data indicate that
there are a number of problems inherent in gene therapy, such as vector toxicity, difficulties
in increasing transfection efficiencies and protein expression at the appropriate time and
site, and the problem of obtaining adequate mutants (in the case of NFκB) due to the contro‐
versy regarding NFκB activation [136]. Although non-viral vectors (such as naked DNA and
liposomes) are likely to present fewer toxic or immunological problems, they suffer from in‐
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efficient gene transfer [136]. In addition, LT is an emergency procedure in most cases, which
leaves very little time to pre-treat the donor with genetic approaches. Efforts to reduce the
time between gene therapy and LT might open new venues for preventative gene therapy
[12]. Currently, viral vectors hydrodynamic injection and cationic liposomes are the main
methods for delivering siRNA in vivo. While viral vectors are associated with severe side ef‐
fects, other methods require large volume and high injection speed, which are not clinically
applicable [135]. Systemic administration of small interfering RNA (siRNA) may cause glob‐
ally nonspecific targeting of all tissues, which impedes clinical use.
9.3. Cell therapy – Hepatocyte transplantation
The liver was among the first organs considered for strategies based on the transplantation
of isolated cells. The first hepatocyte transplant was performed to treat the Gunn rat, the ani‐
mal model for Crigler-Najjar syndrome, which is congenitally unable to conjugate bilirubin
and consequently exhibits life long hyperbilirubinemia. The transplant resulted in a de‐
creased plasma bilirubin concentration. Later, isolated hepatocytes were transplanted into
rats with liver failure induced by dimethylnitrosamine. These experiments demonstrated
that hepatocyte transplantation could potentially be used for the treatment of liver failure
and innate defects of liver-based metabolism. More than 30 years later, these models are still
used in work to improve hepatocyte engraftment and/or function [137].
Many studies have shown that hepatocytes transplanted into rodents via the spleen or the
portal vasculature enter through portal vein branches and are entrapped in proximal hepatic
sinusoids; consequently, the hepatocytes are distributed predominantly in periportal re‐
gions of the hepatic lobules. Transplanted hepatocytes cause both portal hypertension and
transient I/R injury. The portal hypertension, in experimental animals at least, usually re‐
solves within 2 to 3 hours with no obvious long-term detrimental effects, and microcircula‐
tory abnormalities disappear within 12 hours. Numerous hepatocytes (up to 70% of
transplanted cells) remain trapped in the portal spaces, and most of them are destroyed by
the phagocytic responses of KC, which are activated shortly after deposition of hepatocytes
in liver sinusoids [138]. The remaining cells translocate from sinusoids into the liver plates
through a process involving disruption of the sinusoidal endothelium and release of vascu‐
lar endothelial growth factor by both host and transplanted cells. In rodents, hepatic remod‐
eling is complete within 3 to 7 days, and the engrafted cells become histologically
indistinguishable from host cells. Transplantation of 2 x 107 hepatocytes in rats has led to the
engraftment of about 0.5% of the transplanted cells in the recipient livers [139]. Only hepato‐
cytes harboring a selective advantage for survival/proliferation can efficiently repopulate a
recipient liver, and as a result, many repopulation strategies have been developed using ap‐
proaches involving the induction of acute or chronic liver injury [137]. Despite decades of
research, the processes and factors underlying cell engraftment and in situ proliferation are
only partially understood, and a good understanding of these mechanisms is essential for
the development of new and efficient treatments of human liver diseases. The prevention of
early loss of transplanted cells would undoubtedly improve hepatocyte transplantation.
First, it has been recently shown that cell-cell interactions between transplanted hepatocytes
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and hepatic stellate cells modulate hepatocyte engraftment in rat livers. After cell transplan‐
tation, soluble signals activating hepatic stellate cells are rapidly induced along with early
up-regulated expression of matrix metalloproteinases and their inhibitors [140]. Second, the
interaction between integrin receptors and the extracellular matrix plays a role in cell en‐
graftment. Third, hepatocytes express soluble and membrane-bound forms of tissue factor–
dependent activation of coagulation and exert tissue factor–dependent hepatocyte-related
procoagulant activity [137].
Gene Specie Ischemia Vector Effect
Bcl-2 Mouse Warm ischemia Adenovirus ↓ Apoptosis and Necrosis ↑ Survival
eNOS Mouse Warm ischemia Adenovirus ↓ Liver injury
SOD Mouse/Rat Warm ischemia Adenovirus ↓ Liver injury
IL-13 Mouse/Rat Cold ischemia Adenovirus ↓ Liver injury, Neutrophil infiltration, TLR4activation, Apoptosis ↑ HO-1 expression, Survival
Bag-1 Rat Cold ischemia Adenovirus ↓ Liver injury, Neutrophil infiltration
CD40Ig Rat Cold ischemia Adenovirus ↓ Liver injury, Neutrophil accumulation, Apoptosisand Necrosis
IkB Rat Cold ischemia Adenovirus ↓ Liver injury
HO-1 Rat Cold ischemia Adenovirus ↓ Liver injury, Macrophage infiltration, iNOS ↑Survival
Ferritin Rat Cold ischemia Adenovirus ↓ Liver injury, Apoptosis
IL-1R
antagonist Rat Warm ischemia
Cationic
liposomes ↓ Liver injury ↑ Survival
SOD Mouse Warm ischemia Polyplexes ↓ Liver injury ↑ Antioxidative enzyme activity
Catalase Mouse Warm ischemia Polyplexes ↓ Liver injury ↑ Antioxidative enzyme activity
SK2 Mouse Warm ischemia siRNA ↓ Liver injury, Apoptosis ↑ survival
Caspase-3 Mouse Warm ischemia siRNA ↓ Liver injury, Neutrophil infiltration
Caspase-8 Mouse Warm ischemia siRNA ↓ Liver injury, Neutrophil infiltration
TLR4 Mouse Warm ischemia siRNA ↓ Liver injury, Neutrophil infiltration, ROS,Inflammation
Adiponectin Rat Warm ischemia siRNA ↓ Liver injury
Table 3. Summary of gene therapy using specific target genes in hepatic ischemia-reperfusion
In recent years, the development of different animal models has allowed significant progress
in hepatocyte transplantation. In rats, the occlusion of portal branches of the two anterior
liver lobes results in a regeneration response in the remaining nonoccluded lobes leading to
their hypertrophy. This procedure, portal branch ligation, favors efficient retroviral trans‐
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duction of hepatocytes in vivo. Furthermore, hepatic tissue engineering using primary hepa‐
tocytes is an emerging therapeutic approach to liver diseases. Two recent studies reported
engraftment of functional hepatocytes in a neovascularized subcutaneous cavity in mice. A
method to manipulate uniform sheets of hepatic tissue allowing the formation, in vivo, of a
3-dimensional miniature liver system that maintained its biological function for several
months has been also described [137,139]. In the view of clinical practice, treatment of fulmi‐
nant hepatic failure patients by hepatocyte transplantation has been attempted by a number
of investigators [141]. In one report, patients who received a hepatocyte transplant, one pa‐
tient fully recovered and three were successfully bridged to OLT [141]. In a prospective
study of five patients who were transplanted with cryopreserved human hepatocytes, three
patients were successfully bridged to OLT [142]. Other reports have described clinical im‐
provement and relatively longer survival in hepatocyte- transplanted patients [143] but poor
final outcome has also been reported, possibly related to immunosuppression, inadequate
number of transplanted cells, and limited engraftment time [137].
Figure 6. Mechanisms of Ischemic preconditioning in hepatic ischemia-reperfusion injury. AMPK, AMP-activated pro‐
tein kinase; ATP, adenosine triphosphate; ET, endothelin; GSH, glutathione; HO-1, heme oxygenase 1; HSP72, heat
shock protein 72; IL, interleukin; JNK, c-Jun N-terminal kinase; NO, nitric oxide; PKC, protein kinase C; PPAR, peroxi‐
some proliferator-activated receptor; RAS, renin-angiotensin system; ROS, reactive oxygen species; SOD, superoxide
dismutase; TNF, tumor necrosis factor; XDH/XOD, xanthine/xanthine oxidase




The response of hepatocyte to ischemia never ceases to surprise. In fact, contrary to what
might be expected, the induction of consecutive periods of ischemia in the liver does not in‐
duce an additive effect in terms of hepatocyte lesions. Ischemic preconditioning (IP) based
on brief periods of ischemia followed by a short interval of reperfusion prior to a prolonged
ischemic stress protects the liver against I/R injury by regulating different cell types and
multiple mechanisms such as energy metabolism, microcirculatory disturbances, leukocyte
adhesion, KC activation, proinflammatory cytokine release, oxidative stress, apoptosis and
necrosis [96] (Figure 6). This is an advantage in relation with the use of drugs that exerts its
action on a specific mechanism. The benefits of IP observed in experimental models of hep‐
atic warm and cold ischemia [96] prompted human trials of IP. To date, IP has been success‐
fully applied in human liver resections in both steatotic and non-steatotic livers but
unfortunately, it proved ineffective in elderly patients [144]. Preliminary clinical studies
have reported the benefits of IP in LT [145,146]. IP may also have a role in the transplanta‐
tion of small grafts whose pathophysiology overlaps with I/R injury. Additional random‐
ized clinical studies are necessary to confirm whether this surgical strategy can be
commonly used in clinical liver surgery.
10. Conclusion and perspectives
From the data obtained in experimental models of hepatic I/R, we can state that I/R injury is
a multifaceted and intriguing phenomenon. The increasing use of marginal donors in major
liver surgery and the fact that these organs are more susceptible to ischemia highlight the
need for further research directed at the mechanisms of I/R injury. Machine perfusion has
been criticized for its complicated logistics and for possibly damaging the organ and vital
structures such as the endothelium. On the contrary, NMP fulfils all ideal organ preserva‐
tion criteria by avoiding hypoxia and hypothermia. Responses to the strategies aimed at re‐
ducing hepatic I/R injury might depend on the surgical procedure, type of liver and
percentage of hepatic ischemia. Further research is required to elucidate whether the phar‐
macological approaches presented in this review can be translated into liver surgery associ‐
ated with hepatic resections and LT. Advances in molecular biology have provided new
opportunities to reduce liver I/R injury using gene therapy. However, there are a number of
problems inherent in gene therapy, such as vector toxicity and difficulties in increasing
transfection. Liver-cell transplantation is at an early stage. Numerous approaches to isolat‐
ing stem cells of hepatic or extrahepatic origin, including embryonic stem cells, are being de‐
veloped. However, extensive work is still required to assess the number of cells that need to
be expanded and differentiated, and the functionality of the different cell types needs to be
carefully addressed in animal models. Surgical strategies such as IP affect multiple aspects
of I/R injury, whereas pharmacological approaches often affect only a few mediators and
might have systemic side effects.
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